Overview
- The FDA on Monday required makers of all GLP‑1 receptor agonists to add a warning about non‑arteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden, often permanent, painless vision loss in one eye.
- In a meta-analysis of clinical trials the agency identified 15 probable NAION events among roughly 134,000 patients and estimated an incidence of about 6.4 versus 3.8 cases per 100,000 person‑years for GLP‑1 recipients compared with controls.
- The agency reviewed clinical trials, animal studies, observational research and postmarket reports and told clinicians to have patients report sudden visual changes immediately, to refer suspected cases to an ophthalmologist, and to consider stopping the GLP‑1 if NAION is suspected.
- FDA scientists said they could not identify a biological mechanism linking GLP‑1 drugs to NAION and drugmakers have disputed a confirmed causal link while thousands of consolidated lawsuits alleging vision loss proceed.
- European regulators had already added NAION warnings to some GLP‑1 labels and earlier studies, including a 2025 analysis implicating prolonged semaglutide use, helped prompt the U.S. review and will likely shape further research and litigation.